Medicare Rx and the Sequester Impact: Making Headlines, But is There a Commercial Impact?
This article was originally published in RPM Report
Two large pharmaceutical manufacturers weigh in on whether the sequester is impacting their injectables business. The answer so far: not really. The same story goes for the sequester and Part D, though Lilly is seeing higher than expected Part D discounts in 2013.
You may also be interested in...
Cutting the payment level for Medicare Part B drugs is a perennial budget proposal, but never gets very far in Congress. Now, thanks to the sequester, Part B payments have been cut from ASP+6% to ASP+4.3%. Will it stick?
HIV community is pushing back against the change, arguing that revenue lost from reduced reimbursement will cripple providers, which use the extra funds for wrap-around patient support and services.
As MACPAC moves toward formal recommendations, a CBO analysis finds that differential Medicaid rebates for drugs approved through the accelerated pathway could save the federal government up to $1bn over five years.